

Form PTO-1449 (modified)	Atty. Docket No. 12920.0014.PCUS00	Serial No. 107532480
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Robert F. Garry; Srikanta Dash; David H. Coy; Jane A. McKeating	
	Filing Date:	Group: 1648
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Pages 1-2</i>

U.S. Patent Documents (do NOT delete this heading)

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
/SBC/	A1	6,037,348	March 14, 2000	Colacino et al.			
/SBC/	A2	5,747,239	May 5, 1998	Wang et al.			

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1						

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/SBC/	C1	Robert F. Garry, et al., "Proteomics Computational Analysis Suggest that Hepatitis C Virus E1 and Pestivirus E2 Envelope Glycoproteins and Truncated Class II Fusion Proteins," <i>Virology</i> , 307:255-265 (2003).
/SBC/	C2	Hoffman-LaRoche and Trimeris, "Roche and Trimeris Announce 24-Week Results from Second Pivotal Study of HIV Inhibitor T-20", trimeris.com/news/pr/2002/020516.html . (2002)
/SBC/	C3	Richard J. Kuhn et al., "Structure of Dengue Virus: Implications for Flavivirus Organization, Maturation, and Fusion", <i>Cell</i> , 108:717-725 (2002).
/SBC/	C4	R.J. Medinas et al., "C-Terminal gp40 Peptide Analogs Inhibit Feline Immunodeficiency Virus: Cell Fusion and Virus Spread", <i>Journal of Virology</i> , 76(18):9079-9086 (2002).
/SBC/	C5	Julien Lescar, et al., "The Fusion Glycoprotein Shell of Semliki Forest Virus: An Icosahedral Assembly Primed for Fusogenic Activation at Endosomal pH", <i>Cell</i> , 105:137-148 (2001).
/SBC/	C6	Tatiana Suárez, "Membrane Interface-Interacting Sequences within the Ectodomain of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein: Putative Role During Viral Fusion", <i>Journal of Virology</i> , 74(17):8038-8047 (2000).
/SBC/	C7	M. Flint et al., "The Role of Hepatitis C Virus Glycoproteins in Infection", <i>Medical Virology</i> , 10:101-117 (2000).
/SBC/	C8	Mike Flint et al., "Functional Analysis of Cell Surface-Expressed Hepatitis C Virus E2 Glycoprotein", <i>Journal of Virology</i> , 73(8):6782-6790 (1999).

EXAMINER: /Stacy B. Chen/

DATE CONSIDERED: 09/25/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. 12920.0014.PCUS00	Serial No. 10/532480
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Robert F. Garry; Srikanta Dash; David H. Coy; Jane A. McKeating	
		Filing Date:	Group:
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Pages 1-2	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)


Exam. Init.	Ref. Des.	Citation
/SBC/	C9	Winfried Weissenhorn et al., "Crystal Structure of the Ebola Virus Membrane Fusion Subunit, GP2, from the Envelope Glycoprotein Ectodomain", <i>Molecular Cell</i> , 2:605-616 (1998).
/SBC/	C10	Carl Wild et al., "A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell-Cell Fusion", <i>Aids Research and Human Retroviruses</i> , 9(11):1051-1053 (1993).
/SBC/	C11	Carl Wild et al., "Peptides Corresponding to a Predictive α -Helical Domain of Human Immunodeficiency Virus Type 1 gp41 are Potent Inhibitors of Virus Infection", <i>Proc. Natl. Acad. Sci. USA</i> , 91:9770-9774 (1994).
/SBC/	C12	William R. Gallaher, "Detection of a Fusion Peptide Sequence in the Transmembrane Protein of Human Immunodeficiency Virus", <i>Cell</i> , 50:327-328 (1987).

EXAMINER: /Stacy B. Chen/

DATE CONSIDERED: 09/25/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



PTO/SB/08a (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
Submission for form 1449A/PTO				Application Number: 10/532,480	
				Filing Date: April 22, 2005	
				First Named Inventor: Robert F. Garry	
				Art Unit: 1648	
				Examiner Name: Chen, S.B.	
Sheet 1 of 1				Attorney Docket Number: 12920.0014.PCUS00	

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/SBC/	A3	US- 5,610,009	05/11/97	Watanabe et al	
/SBC/	A4	US- 4,810,492	03/07/89	Fujita et al	
		US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
/SBC/	B1	WO 01/51673 A1	07-19-2001	Trimeris, Inc.		
/SBC/	B2	WO 00/75337 A1	12-14-2000	Bukh et al.		
/SBC/	B3	EP 0 982 402 A1	03-01-2000	Stichting Instituut voor Dierhouderij en Diergezondheid		
/SBC/	B4	WO 99/55366	11-04-1999	Washington University		

Examiner Signature	/Stacy B. Chen/	Date Considered	09/25/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/532,480
				Filing Date	April 22, 2005
				First Named Inventor	Robert F. Garry
				Art Unit	1648
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	12920.0014.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
/SBC/	C13	VOLKOVA, T.D.; ET AL, " <i>The Protein E 98-113 Sequence as the Fusion Site of Tick-Borne Encephalitis Virus with a Cellular Membrane</i> ", Bioorganicheskaya Khimiya (1998), Vol. 24, No. 9, p. 676-681. (Abstract Only)	
/SBC/	C14	VOLKOVA, T.D., ET AL, " <i>A Monoclonal Antibody That Recognizes The Predicted Tick-Borne Encephalitis Virus E Protein Fusion Sequence Blocks Fusion</i> ", Archives of Virology (1999), Vol. 144, p. 1035-1039.	
/SBC/	C15	ALLISON, S.L., ET AL, " <i>Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E</i> ", Journal of Virology (2001), Vol. 75, No. 9, p. 4268-4275.	
/SBC/	C16	STIASNY, K., ET AL, " <i>Membrane Interactions of the Tick-Borne Encephalitis Virus Fusion Protein E at Low pH</i> ", Journal of Virology (2002), Vol. 76, No. 8, p. 3784-3790.	
/SBC/	C17	CRILL, W.D., ET AL, " <i>Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells</i> ", Journal of Virology (2001), Vol. 75, No. 16, p. 7769-7773.	
/SBC/	C18	BHARDWAJ, S., ET AL, " <i>Biophysical Characterization and Vector-Specific Antagonist Activity of Domain III of the Tick-Borne Flavivirus Envelope Protein</i> ", Journal of Virology (2001), Vol. 75, No. 8, p. 4002-4007.	
/SBC/	C19	REY, F.A., ET AL, " <i>The Envelope Glycoprotein From Tick-Borne Encephalitis Virus at 2 Å Resolution</i> ", Nature (1995), Vol. 375, p. 291-298.	

Examiner Signature	/Stacy B. Chen/	Date Considered	09/25/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/532,480
				Filing Date	April 22, 2005
				First Named Inventor	Robert F. Garry
				Art Unit	1648
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	12920.0014.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
/SBC/	C20	HUNG, S., ET AL, "Analysis of the Steps Involved in Dengue Virus Entry into Host Cells", Virology (1999), Vol. 257, p. 156-167.	
/SBC/	C21	SHAI, Y., "Functional Domains within Fusion Proteins: Prospectives for Development of Peptide Inhibitors of Viral Cell Fusion, Bioscience Reports (2000), Vol. 20, No. 6, p. 535-555.	

Examiner Signature	/Stacy B. Chen/	Date Considered	09/25/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.